Clinical trial

GALLANT 4 Tesaglitazar vs. Glibenclamide

NCT00255541

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2004-09-01

PhasePHASE3

Study timeline

Study start (unknown)2004-09-01Date precision: month

Registry last updated2008-03-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetesverified · MONDO: type 2 diabetes mellitus

Interventions

TesaglitazarDRUG

GlibenclamideDRUG · verified · RxNorm: glyburide

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

MilanItaly1 TaipeiTaiwan1 WarsawPoland1 BudapestHungary1 RomaItaly1 KrakowPoland1 TaichungTaiwan1 NaplesItaly1 LublinPoland1 LiègeBelgium1 BangkokThailand1 BratislavaSlovakia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00255541 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.